New drug combo targets Hard-to-Treat cancers in early trial
NCT ID NCT04501276
First seen Jan 11, 2026 · Last updated May 21, 2026 · Updated 23 times
Summary
This early-phase trial tested a new drug called ADG116, alone or combined with other therapies, in 72 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. The drug works by helping the immune system attack cancer cells, but this is not a cure — it aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ashford Cancer Centre Research
Kurralta Park, Australia
-
Cabrini Hospital
Malvern, Australia
-
Macquarie University
Sydney, Australia
-
Next Oncology
San Antonio, Texas, 78229, United States
Conditions
Explore the condition pages connected to this study.